Are TB-500, GHK-Cu or epitalon FDA-approved?

No. None of them is an FDA-approved drug. In July 2026 an FDA advisory committee narrowly voted to recommend that TB-500 and epitalon be eligible for pharmacy compounding, but the vote is nonbinding and it is not an approval. As of mid October 2026, none of the peptides had been added to the list that allows compounding, and an interim access policy FDA sent to the White House for review on October 14 had not been issued.

What is the actual evidence for TB-500?

Very little in humans. TB-500 is a fragment of thymosin beta-4. In its safety review, FDA noted no identified human exposure data for the fragment, and Sport Integrity Australia says thymosin beta-4 is not approved for human use anywhere in the world and that its safety profile remains largely unknown.

The best-supported use is topical, in skin care. Reviews describe improvements in skin firmness, fine lines and photodamage, and faster wound healing in animal studies. Evidence for injectable GHK-Cu in humans is limited, and FDA flagged possible immune reactions and impurities for the injectable form.

Are peptides banned in sport?

Thymosin beta-4, the parent of TB-500, is listed by the World Anti-Doping Agency under S2 growth factors and is banned in sport at all times. The 2027 Prohibited List, which takes effect January 1, 2027, also names peptides in general as prohibited non-approved substances under S0. Athletes subject to testing should check any peptide with their anti-doping agency before using it.

Peptides, fact vs. hype: TB-500, GHK-Cu and epitalon

Most of the peptides sold as recovery and longevity tools, including TB-500, GHK-Cu and epitalon, rest on animal studies, cell research and small or old human studies, not on large clinical trials. None of them is an FDA-approved drug. In 2026 the federal rules on compounding them started to shift, and an FDA advisory panel narrowly backed some of them over the objections of FDA's own scientists, but that is a change in who may legally prepare them, not proof that they work or are safe.

If a founder friend has been telling you that a peptide fixed his shoulder, his sleep or his biological age, this is the context he probably left out.

Why peptides became the new founder supplement

Peptides are short chains of amino acids. Plenty of real medicines are peptides: insulin is one, and so are the GLP-1 drugs that have reshaped obesity care. That legitimate lineage is part of the marketing appeal. The compounds that circulate in founder group chats borrow the credibility of approved peptide drugs without having gone through the same testing.

The pitch fits the audience. You are training harder than your body would like, sleeping less than you should and carrying a nagging injury from the half-marathon you ran to prove you still could. Someone offers a compound that supposedly speeds tissue repair, tightens skin or lengthens telomeres. It sounds like an optimization problem with a clean answer.

The research tells a messier story, and the regulatory picture changed several times in 2026 alone.

What happened to peptide regulation in 2026?

Compounding pharmacies can legally make certain drugs from bulk ingredients when a physician prescribes them for a specific patient. FDA sorts nominated ingredients into categories. "Category 2" is the list of substances FDA said raise significant safety concerns, which in practice meant compounding pharmacies should not use them.

Several popular peptides sat on that list. FDA's published safety review gave its reasons for each. For TB-500 (thymosin beta-4 fragment), it said the peptide "may pose risk for immunogenicity for certain routes of administration," meaning it could provoke an immune reaction, flagged possible aggregation and impurities, and noted no identified human exposure data. For epitalon, it cited immunogenicity risk and insufficient safety data. For injectable GHK-Cu, it flagged immunogenicity and "limited data in humans to inform safety-related considerations."

Then the politics moved. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the Category 2 list would be moved back to Category 1, with TB-500, GHK-Cu and BPC-157 among them.

peptides on FDA's Category 2 safety-concern list before the 2026 reversal

Pharmacy Times

BPC-157 trials FDA scientists judged too short and small to establish safety

AJMC

FDA-approved drugs among the seven peptides voted on in July 2026

AJMC

The pharmacist writing in Pharmacy Times was blunt about what that means: reclassification "governs compounding legality only; it does not confer FDA approval, validated indications, standardized dosing, or established benefit-risk."

The July 2026 advisory vote was a coin flip

In July 2026, FDA's Pharmacy Compounding Advisory Committee met to vote on seven peptides. It recommended six of them, including TB-500 and epitalon, for the list of substances pharmacies may compound. The margins were thin.

The advisory panel split almost down the middle on every peptide

Committee votes on adding each peptide to the 503A compounding list, July 2026 (number of members)

YesNo

TB-500

BPC-157

KPV

MOTS-c

Source: AJMC, FDA panel backs 6 peptides for compounding (2026)

View data

	Yes	No
TB-500	8	6
BPC-157	8	6
KPV	8	6
MOTS-c	7	5

Epitalon and Semax passed by "similarly tight margins." The more telling detail is who disagreed. According to AJMC's report, "FDA scientists uniformly opposed adding any of the 7 substances," and they concluded that "available studies, including 5 trials of BPC-157, were short in duration, small in sample size, and insufficient to establish safety or effectiveness."

The vote is advisory. As of the meeting, "None of the peptides have been added to the 503A Bulks List, and none is an FDA-approved drug." Formal rulemaking has to follow before compounding becomes legal. On October 14, 2026, HHS and FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review. As of mid October it had not been issued, and FDA had not proposed a rule. Injectable GHK-Cu was not among the seven peptides voted on.

If you were in a board meeting and your own technical team unanimously opposed a decision that then passed 8 to 6, you would not describe the question as settled.

TB-500: what the evidence says

TB-500 is marketed as a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. The recovery pitch (faster healing of tendons, muscles and ligaments) extrapolates from that biology.

The human evidence is thin. FDA noted no identified human exposure data for the fragment. Sport Integrity Australia, the Australian government's anti-doping agency, states that "Thymosin Beta-4 is not approved for human use anywhere in the world" and that animal experiments and clinical trials have looked at conditions including heart disease, eye injuries and wound healing. It adds two warnings worth reading slowly: "There is serious concern that it increases the spread and growth of cancer cells," and "its safety profile remains largely unknown."

Evidence quality: mechanism and animal work, with limited and condition-specific human research on the parent protein, not on the fragment sold for recovery.

Sport status: thymosin beta-4 is listed under WADA's S2.3 growth factors class and is banned in sport at all times. Starting January 1, 2027, the WADA Prohibited List also names peptides in general as prohibited under S0, the class for non-approved substances. If you compete in anything tested, including masters events, that alone settles it.

GHK-Cu: the strongest case is on your skin

GHK-Cu is a copper-binding peptide found naturally in the body. Of the three, it has the most defensible use, and it is also the most boring: skin care.

A 2015 review in BioMed Research International describes GHK as a compound that "stimulates both synthesis and breakdown of collagen and glycosaminoglycans" and reports that in cosmetic use it can "tighten loose skin and improve elasticity, skin density, and firmness" and "reduce fine lines and wrinkles, reduce photodamage, and hyperpigmentation." The review also describes wound healing in rats, mice, pigs and dogs, and gene-expression work suggesting GHK can shift the activity of at least 4,000 human genes.

Treat that last number carefully. Changing gene expression in a lab is a mechanism, not an outcome. Wellness marketing often turns "affects 4,000 genes" into "reverses aging," and the review makes no such claim.

Evidence quality: reasonable for topical cosmetic effects, animal data for wound healing, and limited human data for injection, which is exactly where FDA raised its immunogenicity and impurity concerns.

Epitalon: large claims, thin support

Epitalon is a short synthetic peptide promoted for telomere length, sleep and longevity. The claims are the largest of the three. The support is the thinnest.

FDA's safety review cited a risk of immune reactions "due to aggregation and peptide-related impurities" and insufficient safety data for the routes people actually use. The advisory panel still voted narrowly to recommend it for compounding, over the same unanimous staff opposition. There are no large, independent, randomized human trials showing that epitalon extends life or improves any hard health outcome.

Evidence quality: early and largely preclinical. Any claim that it lengthens your life is a hypothesis presented as a result.

What the evidence says, and what it doesn't

Supported: Some peptides are excellent, well-tested medicines. GHK-Cu has a reasonable evidence base as a topical skin care ingredient.

Unproven in humans: TB-500 for injury recovery. Epitalon for longevity. Injectable GHK-Cu for anything. The evidence is mostly cells, animals and small studies.

Uncertain on safety: Immune reactions, impurities and, for thymosin beta-4, a stated concern about cancer growth. FDA scientists judged the data insufficient even for BPC-157, the most studied of the group.

Not what it sounds like: A change in compounding rules, or a favorable advisory vote, is not FDA approval. It does not establish a dose, an indication or a benefit-to-risk profile.

If you are considering any peptide, hormone or unapproved compound, talk with a physician first, preferably one who will tell you plainly when the evidence is not there. That conversation matters even more if you have a personal or family history of cancer.

Laboratory shelves lined with rows of glass chemical bottles — A compound being legal to prepare and a compound being proven to work are two different questions.Photo: Adam Bezer on Unsplash

What a founder can actually do this week

The appeal of peptides is that they promise to compress recovery. The unglamorous levers that do that have better evidence and fewer unknowns.

Diagnose the injury. If a tendon or joint has hurt for more than a few weeks, see a sports medicine physician or physical therapist. A clear diagnosis and a loading plan will outperform a vial from a group chat.

Audit your recovery inputs. Look honestly at the last seven nights of sleep. Tissue repair and hormone rhythms depend on it, and it is the first thing a founder sacrifices. The wind-down routine in meditation for sleep for executives is a practical place to start.

Price in the unknowns. Before trying anything unproven, write down what you would need to see to believe it works, and what side effect would make you stop. If the only evidence is a testimonial, you are the trial, without an ethics board or a data safety monitor.

Check your sport's rules. If you race, lift or play in tested competition, check any substance with your anti-doping agency first.

Notice what you are really trying to fix. Many founders reach for a recovery compound when the real deficit is chronic load. If that sounds familiar, read what chronic stress does to a founder's body.

The recovery work that has no side effects

Underneath the peptide conversation is a real need: founders want to recover faster so they can keep performing. The most reliable recovery system you have is your own nervous system, and it responds to training. Slow breathing, a regular sleep window and a daily practice of downshifting after high-stakes moments all move the body toward repair, and none of them carries an immunogenicity warning.

That is where Cinder fits. We offer private 1:1 meditation coaching for founders and executives, built around stress regulation and sleep as skills that hold up under a hard quarter. It will not heal a torn tendon. It will help you stop running your body at a pace that keeps creating them.

A better recovery stack starts with the basics

Peptide regulation will keep moving, and some of these compounds may eventually earn better evidence. For now, the honest read is simple: interesting biology, thin human data, real safety questions and a regulatory status that is easy to mistake for approval. Build the foundation first.

Apply for private coaching